Norway
BerGenBio randomises first patient in Covid-19 treatment study
A lead candidate of the company, bemcentinib is an oral inhibitor of AXL.
Ultimovacs Phase II melanoma trial concludes subject recruitment
Ultimovacs’ cancer vaccine demonstrates overall survival in Phase I melanoma trial
Nykode concludes subject enrolment in Phase II cervical cancer vaccine trial
Nykode doses first participant in Phase I/II Covid-19 vaccine trial
BerGenBio concludes subject enrolment in Phase II AML drug trial
How BerGenBio became a frontrunner in UK hunt for Covid-19 treatment
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
